Core Insights - Tevogen Bio Holdings Inc. is modifying its long-term stock incentive program to align with specific company milestones, including revenue targets, applicable to all eligible employees and consultants [1][7]. Company Overview - Tevogen has transitioned from a T cell therapy biotech to a diversified healthcare company, aiming to launch at least four blockbuster products by 2030 and generate revenue in 2026 through current programs, asset acquisitions, and joint ventures [2]. - The company operates on principles of affordability, efficiency, and scientific rigor, utilizing advanced AI and precision T cell therapy platforms to develop life-saving therapies across various therapeutic areas [2]. Product Development - Tevogen Bio's lead initiative has successfully completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, with a pipeline that includes programs in virology, oncology, and neurology based on the proprietary ExacTcell™ platform [3]. - Tevogen.AI aims to enhance drug development by improving target detection, reducing failure rates, and optimizing clinical trial designs through predictive technologies, leveraging cloud services from major tech providers [4]. Strategic Initiatives - The company is exploring future initiatives that may encompass domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to promote sustainable innovation and broaden patient access to healthcare [5].

Core Insights - Cue Biopharma, Inc. is making significant progress in advancing its Immuno-STAT platform and lead autoimmune asset, CUE-401, aimed at addressing unmet needs in autoimmune disease treatment [2][4] Business Highlights - The company reported collaboration revenue of $2.1 million for Q3 2025, down from $3.3 million in Q3 2024, attributed to the timing of revenue recognition from collaborations [4] - Research and development expenses decreased to $4.8 million in Q3 2025 from $9.4 million in Q3 2024, mainly due to reduced clinical trial costs and lower employee compensation [5] - General and administrative expenses increased to $4.9 million in Q3 2025 from $2.9 million in Q3 2024, primarily due to a one-time employee severance accrual and higher professional fees [6] Financial Results - The net loss for Q3 2025 was $7.4 million, compared to a net loss of $8.7 million in Q3 2024 [9] - Total operating expenses for Q3 2025 were $9.7 million, down from $12.2 million in Q3 2024 [9] - The company had cash and cash equivalents of $11.7 million as of September 30, 2025, down from $22.5 million at the end of 2024 [11] Strategic Developments - Cue Biopharma announced a strategic collaboration and license agreement with ImmunoScape, which includes upfront payments totaling $15 million and a 40% equity stake in ImmunoScape [7] - The company appointed Usman Azam, M.D., as President and CEO, effective September 29, 2025, to lead the next stage of growth [7] - CUE-401 is designed as a tolerogenic bifunctional molecule aimed at re-establishing immune tolerance and balance [7][12]

Core Insights - Tevogen Bio Holdings Inc. has achieved a clinical milestone by completing T cell target identification for five additional human leukocyte antigen (HLA) restrictions, expanding the accessibility of its ExacTcell™ platform [1][4] - The identification of these additional HLA targets allows for the treatment of approximately 65% of the U.S. population, significantly increasing coverage for minority populations [2][3] - The investigational T cell therapy, TVGN 489, has demonstrated 100% viral clearance in high-risk patients with COVID-19, with no reinfections or cases of Long COVID reported [7] Company Developments - The ExacTcell™ platform employs advanced immunological screening to identify immune system targets across various HLA types, aiming to provide treatments for a broader range of infectious diseases and cancers [4] - The selection of additional HLA targets is aimed at ensuring equitable access to treatments for patients of diverse racial and ethnic backgrounds [3] Market Context - Long COVID has affected approximately 35 million U.S. adults, leading to an estimated economic burden of $2.6 trillion to $3.7 trillion, highlighting the urgent need for effective treatments like Tevogen's T cell therapies [3] - The expansion of patient eligibility through multi-HLA targeting is a significant step towards universal T cell therapeutics, enhancing the potential market for Tevogen's products [7]

As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. 333-280414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on July 31, 2024 Registration No. 333-280414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on July 23, 2024 Registration No. 333-280414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on July 23, 2024 Registration No. 333-280414 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on June 21, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1597194 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 15 Independence Boul ...